Zoetis Inc. (ZTS) Stock

Zoetis Inc. (ZTS) is a Healthcare stock trading at $76.55 (as of 2026-07-17), with a market capitalization of $32.09B and a trailing P/E of 12.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health products, including medicines, vaccines, and diagnostic offerings, for use with livestock and companion animals. Its portfolio includes products such as anti-infectives, parasiticides, and other therapeutic categories, as well as point-of-care testing, instruments and reagents, and rapid diagnostic tests.

Understand Zoetis Inc.: how it makes money

Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products, and it makes money by selling those products to support livestock and companion animal health.

Zoetis converts product revenue from its animal health portfolio (across livestock and companion animals) into operating profit, with profitability reflected in its operating margin.

Revenue by segment (latest quarter)
US$1.1B
Intl$1.1B

Business quality (Strong): Clear operating margin data is provided (33.5%), and revenue is split between U.S. and international exposure, but no gross margin or more specific operating metrics beyond revenue are included in the provided facts.

Valuation: At 13× earnings, ZTS trades 25% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Broad animal health portfolio: The company commercializes animal health medicines, vaccines, and diagnostic products across multiple species, including livestock (cattle, swine, poultry, fish, and sheep) and companion animals (dogs, cats, and horses).
  • Geographic diversification: Revenue is shown as split between U.S. and international segments (both around 1.1 USD_B in the provided candidates).

Bear case

  • Species mix concentration risk: Companion animal revenue is shown as 1.6 USD_B (Q4 candidate), so adverse changes in companion animal demand or product performance could weigh on overall results.
  • Product and disease-cycle uncertainty: Because the business depends on animal health medicines and vaccines, results could be pressured if animal health needs change or if specific product categories underperform.
Valuation — source: SEC EDGAR (first-party)
Price$76.55
Market Cap$32.09B
P/E Ratio12.1
EV / EBITDA10.3
Price / Book9.93
Price / Sales3.37
FCF Yield3.2%
DCF Value (model)$95.15
DCF Upside vs Price24.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$9.47B
Net Margin28.2%
Revenue Growth (YoY)1.9%
EPS Growth (YoY)0.7%
FCF Growth (YoY)-33.6%
Financial Health — source: SEC EDGAR
Altman Z-Score4.52 (safe)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Stock P/E12.1
Sector P/E (Healthcare)21.4
Industry P/E (Pharmaceutical Products)17.0
vs Sector-43.4%
vs Industry-28.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($6.01B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOKristin C. Peck
Employees13,800
CountryUS
IPO Date2013-02-01

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by market cap; US-domiciled)

  • Merck & Co., Inc. (MRK)
  • Abbott Laboratories (ABT)
  • Pfizer Inc. (PFE)
  • Bristol-Myers Squibb Company (BMY)
  • Vertex Pharmaceuticals Incorporated (VRTX)
  • Regeneron Pharmaceuticals, Inc. (REGN)
  • Biogen Inc. (BIIB)
  • Moderna, Inc. (MRNA)
ZTS earnings history · ZTS institutional & insider holders · ZTS KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-17.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.